irritable bowel syndrome; diarrhea of viral and chronic origin; prevention and treatment of colitis as part of complex therapy; diarrhea caused by prolonged use of antibiotics.
Enterol №30 Composition
active substance: 1 capsule contains boulardi saccharomyces CNCM I-745 (lyophilized cells) 250 mg;
Enterol №10 excipients: lactose monohydrate, magnesium stearate.
Enterol №30 Dosage form
Basic physical and chemical properties: white opaque gelatin capsules containing a light brown powder with a specific odor.
Antidiarrheal microbial drugs. Boulardi saccharomyces. ATX code A07F A02.
Enterol® 250 normalizes the intestinal microflora and has a pronounced etiopathogenetic antidiarrheal effect. During its passage through the gastrointestinal tract, Saccharomyces boulardii CNCM I-745 exert a biological protective effect against normal intestinal microflora.
The main mechanisms of action of Saccharomyces boulardii CNCM I-745:
direct antagonism (antimicrobial effect), which is due to the ability of Saccharomyces boulardii CNCM I-745 to inhibit the growth of pathogenic and opportunistic microorganisms and fungi that disrupt the intestinal biocenosis, such as: Clostridium difficile, Clostridium pneumoniae, Staphylococcus auroseuda , Candida albicans, Salmonella typhi, Salmonella enteritidis, Escherichia coli, Shigella dysenteriae, Shigella flexneri, Klebsiella, Proteus, Vibrio cholerae, and Enthamoeba hystolitica, Lambliae; Enterovirus, Rotavirus;
the antitoxic effect is due to the production of proteases that break down the toxin and act on the enterocyte receptor with which the toxin binds (especially with respect to cytotoxin A, Clostridium difficile);
the antisecretory effect is due to a decrease in cAMP in enterocytes, which leads to a decrease in the secretion of water and sodium into the intestinal lumen;
strengthening of nonspecific immune protection by increasing the production of IgA and secretory components of other immunoglobulins;
the enzymatic effect is due to an increase in the activity of small intestine disaccharidases (lactase, sucrase, maltase);
the trophic effect on the mucous membrane of the small intestine is observed due to the release of spermine and spermidine.
The genetically determined resistance of Saccharomyces boulardii CNCM I-745 to antibiotics justifies the possibility of their simultaneous use with antibiotics to protect the normal biocenosis of the digestive tract.
After taking the drug, a high concentration of Saccharomyces boulardii CNCM I-745 in the large intestine is quickly achieved, which is maintained for 24 hours. Saccharomyces boulardii CNCM I-745 does not penetrate the systemic circulation and mesenteric lymph nodes. After the end of treatment, Saccharomyces boulardii CNCM I-745 is completely excreted in the feces within 3-5 days.
Prevention and treatment of antibiotic-associated colitis and diarrhea.
Acute and chronic bacterial diarrhea.
Acute viral diarrhea.
Irritable Bowel Syndrome.
Pseudomembranous colitis and diseases caused by Clostridium difficile.
Diarrhea associated with long-term enteral nutrition.
Hypersensitivity to any component of the drug. The drug is contraindicated in patients with a central or peripheral venous catheter; patients being treated in the intensive care unit; immunocompromised patients, such as: HIV-infected, cancer patients, with a transplanted organ, receiving chemotherapy and / or radiation therapy and / or long-term high doses of corticosteroids.